ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT07021989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium
Study identification
- NCT ID
- NCT07021989
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Michael Spinner, MD
- Other
- Enrollment
- 38 participants
Conditions and interventions
Interventions
- Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT) Procedure
- Foresight CLARITY™ LDT Device
- Gemcitabine Drug
- Liposomal Doxorubicin Drug
- Non-investigational, involved site radiotherapy (ISRT) Radiation
- Pegfilgrastim Drug
- Pembrolizumab Drug
- Vinorelbine Drug
Procedure · Device · Drug + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2026
- Primary completion
- Mar 30, 2029
- Completion
- Oct 30, 2033
- Last update posted
- Mar 16, 2026
2026 – 2033
United States locations
- U.S. sites
- 6
- U.S. states
- 1
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Davis | Davis | California | 95616 | — |
| University of California San Francisco-Fresno | Fresno | California | 93701 | — |
| University of California Irvine | Irvine | California | 92617 | — |
| University of California, San Diego | La Jolla | California | 92093 | — |
| Unversity of California, Los Angeles | Los Angeles | California | 90095 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07021989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07021989 live on ClinicalTrials.gov.